Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
06/08/2026 17:35
BRIEF-MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients Aug 6 (Reuters) - MiNK Therapeutics Inc INKT.O:
MINK THERAPEUTICS - NO MAJOR SERIOUS ADVERSE EVENTS ATTRIBUTED TO AGENT-797 IN FIRST PATIENTS
MINK THERAPEUTICS - FIRST AGENT-797 PATIENTS ALIVE AND AFEBRILE AT DAY 28 WITH IMPROVED OXYGENATION
MINK THERAPEUTICS - ENROLLMENT CONTINUES IN LVIV WITH U.S. SITES OPENING; ADDITIONAL DATA EXPECTED EARLY 2027
Source text: ID:nGNXcdvs6B
Further company coverage: INKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mink Therapeutics
See all newsMiNK Therapeutics Q2 loss narrows on expense discipline
Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's